ClinicalTrials.gg
CompletedNCT03067194Updated Jan 30, 2020

The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients

A Phase 4 interventional study of Celecoxib 100 MG and Celecoxib 200mg in Osteoarthritis Hand, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-30.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing celecoxib in Osteoarthritis — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis.

Enrollment
9th of 14
117 · median 150
Started
2016
the only one that year
Phase 4
10 of 14
1 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Chong Kun Dang Pharmaceutical

Among the 14 studies testing celecoxib in Osteoarthritis, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 10 in phase 4, and was the 13th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of Celecoxib capsule in hand osteoarthritis patients.

Read the detailed description

This is a six-weeks, open-label, multi-center, randomized study. Patients take Celecoxib 200mg capsule once a day or Celecoxib 100mg capsules twice per day. If patients do not tolerate the pain, they are able to take Acetaminophen as a rescue medication during 6 weeks.

03

Conditions studied

  • Osteoarthritis Hand

Browse trials for

Keywords

  • Osteoarthritis Hand
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Agreement with written and 19 years of age and older
  • Patients history of OA of hand according to ACR criteria
  • The 100mm Pain VAS is over 40mm

Exclusion criteria

Exclusion Criteria:

  • History of OA of hand surgery
  • Intra-articular injections within 3 months
  • History of OA of hand infections within 3 months
  • Who had taken a drug that has a control of result in clinical trial by investigator's decision
  • Pregnant women, nursing mothers or Fertile women who not practice with appropriate methods
  • hepatic, renal, cardiovascular diseases
  • Any history of adverse reaction to the study drugs
  • Patients with gastrointestinal ulcers or bleeding disorders
  • Finger joint injury within 6 months
  • Who had following results after examination

    1. K ≥ 5.5mEq/L
    2. ≤ 30ml/min/1.73m\^2
  • Patients on any other clinical trial or experimental treatment in the past 3 months
  • Taking narcotic analgesics or patches
  • History of drug abuse or alcoholism
  • Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders
  • An impossible one who participates in clinical trial by investigator's decision
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
117 participants (actual)

Study arms

  • Active comparator
    Celecoxib 100mg

    Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks

    Drug: Celecoxib 100 MG

  • Active comparator
    Celecoxib 200mg

    Celecoxib 200mg, Oral, QD(once daily), During 6 weeks

    Drug: Celecoxib 200mg

Interventions

  • Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks

    Also known as: Celecoxib 100mg capsule

  • Celecoxib 200mg, Oral, QD(once daily), During 6 weeks

    Also known as: Celecoxib 200mg capsule

06

What researchers measure

Primary outcomes

  1. The change of 100mm Pain VAS score at 6 weeks relative to the baseline value of each group

    Time frame: baseline, 6weeks

Secondary outcomes

  1. Changes in each item of K-AUSCAN at 6 weeks relative to the baseline value of each group

    Time frame: baseline, 6weeks

  2. The total point change of K-AUSCAN at 6 weeks relative to the baseline value of each group

    Time frame: baseline, 6weeks

  3. Total score change of insomnia severity at 6 weeks relative to the baseline value of each group

    Time frame: baseline, 6weeks

  4. Total dosing days of acetaminophen for 6 weeks in each group

    Time frame: 6weeks

  5. The total dose of acetaminophen for 6 weeks in each group

    Time frame: 6weeks

  6. Percentage of subjects using acetaminophen for 6 weeks in each group

    Time frame: 6weeks

Other outcomes

  1. Safety assessed by the incidence of adverse event

    Time frame: up to 6weeks

  2. laboratory test(Hematology test, Blood chemistry test, Urinalysis)

    Time frame: up to 6weeks

07

Study locations

1 site
  • Soon Chun Hyang University Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jul 2017, 6 months.

Of 63 phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 60. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2017
First posted
Mar 1, 2017
StartActual
Dec 27, 2016
Primary completionActual
Jul 10, 2017
CompletionActual
Nov 20, 2018
Last update
Jan 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03067194
Responsible party
Sponsor
First posted
Mar 1, 2017
Start date
Dec 27, 2016
Primary completion
Jul 10, 2017
Completion
Nov 20, 2018
Last update
Jan 30, 2020

Study contacts

Hyun Sook Kim
principal investigator · Soonchunhyang University Hospital
Chan Hong Jeon
principal investigator · Soonchunhyang University Hospital
Sung Hae Jang
principal investigator · Soonchunhyang University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion